NASDAQ · PRCT
Healthcare · Medical - Devices
$19.30
Up+$0.14 (+0.73%)
Updated Sep 16, 2026, 4:08 PM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PRCT closed at $19.30 after 20 trading sessions, down 9.47% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $20.82 | $20.91 | $19.23 | $19.30 | 2M |
| Sep 14, 2026 | $20.58 | $21.50 | $20.58 | $21.02 | 1.68M |
| Sep 11, 2026 | $20.23 | $20.67 | $19.55 | $20.38 | 1.57M |
| Sep 10, 2026 | $20.42 | $20.65 | $19.76 | $20.07 | 975.55K |
| Sep 9, 2026 | $21.22 | $21.44 | $20.60 | $20.74 | 1.07M |
| Sep 8, 2026 | $22.485 | $22.56 | $20.85 | $21.35 | 1.78M |
| Sep 4, 2026 | $21.19 | $22.835 | $20.89 | $22.76 | 1.28M |
| Sep 3, 2026 | $22.13 | $22.49 | $20.84 | $21.37 | 861.09K |
| Sep 2, 2026 | $20.86 | $22.09 | $20.80 | $21.97 | 1.28M |
| Sep 1, 2026 | $21.15 | $21.23 | $20.33 | $20.91 | 1.07M |
| Aug 31, 2026 | $20.76 | $21.26 | $20.375 | $21.20 | 939.86K |
| Aug 28, 2026 | $20.76 | $20.97 | $20.42 | $20.83 | 687.27K |
| Aug 27, 2026 | $21.34 | $21.34 | $20.465 | $20.60 | 1.11M |
| Aug 26, 2026 | $21.28 | $21.41 | $20.88 | $21.07 | 770.29K |
| Aug 25, 2026 | $21.25 | $21.67 | $21.04 | $21.60 | 595.43K |
| Aug 24, 2026 | $21.66 | $21.68 | $21.035 | $21.25 | 756.58K |
| Aug 21, 2026 | $20.77 | $22.00 | $20.77 | $21.68 | 821.95K |
| Aug 20, 2026 | $21.87 | $21.90 | $20.69 | $20.73 | 1.29M |
| Aug 19, 2026 | $21.69 | $22.2025 | $21.595 | $21.91 | 635.99K |
| Aug 18, 2026 | $21.10 | $21.88 | $21.10 | $21.32 | 819.53K |
The latest Smart Investors Daily articles mentioning PRCT.
PRCT research
Company profile and research snapshot.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | William Blair | Market Perform | — |
| Aug 5, 2026 | Piper Sandler | Overweight | — |
| Aug 5, 2026 | TD Cowen | Buy | — |
| Aug 5, 2026 | Evercore ISI Group | Outperform | — |
| Jul 6, 2026 | Truist Securities | Hold | — |
No generated briefing is available yet.
SeekingAlpha · Mar 30, 2026
PROCEPT BioRobotics trades at 2.9x forward EV/2026E revenue, a deep discount to peers, despite 27-33% guided revenue growth. Learn why PRCT stock is a buy.
SeekingAlpha · Mar 6, 2026
PROCEPT BioRobotics Corporation (PRCT) TD Cowen 46th Annual Health Care Conference March 2, 2026 11:50 AM ESTCompany ParticipantsLarry Wood - President, CEO...
Benzinga · Mar 6, 2026
Baird analyst David Rescott initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Neutral rating and announces Price Target of $30.
SeekingAlpha · Mar 4, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRCT.
